Expression of D2-40 in lymphatic endothelium of normal tissues and in vascular tumours

Histopathology

Volumn 46, Issue 4, 2005, Pages 396-402

  Fukunaga, Masaharu ^a,b  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

D2 40; Immunohistochemistry; Lymphatic endothelium; Vascular tumour

Indexed keywords

CD31 ANTIGEN; EPITOPE; FORMALDEHYDE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY D2 40; PARAFFIN; SIALOGLYCOPROTEIN MR 40 000; UNCLASSIFIED DRUG;

ANGIOSARCOMA; ARTICLE; CELL DIFFERENTIATION; COLON; CONTROLLED STUDY; DABSKA TUMOR; ENDOTHELIUM CELL; EPITHELIOID CELL; GLOMUS TUMOR; HEMANGIOENDOTHELIOMA; HEMANGIOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPOSI SARCOMA; LYMPH NODE; LYMPH VESSEL ENDOTHELIUM; LYMPHANGIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN; SKIN TUMOR; SOFT TISSUE; SOFT TISSUE TUMOR; SPINDLE CELL; STOMACH; VASCULAR TUMOR;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD31; ANTIGENS, NEOPLASM; ENDOTHELIUM, LYMPHATIC; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC SYSTEM; NEOPLASMS, VASCULAR TISSUE;

EID: 17144427710     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2005.02098.x     Document Type: Article

References (14)

1. Folpe AL, Veikkola T, Valtola R., Weiss SW. Vascular endothelial growth factor receptor-3 (VEGFR-3): a marker of vascular tumors with presumed lymphatic differentiation, including Kaposi's sarcoma. Kaposiform and Dabska-type hemangioendotheliomas, and a subset of angiosarcomas. Mod. Pathol. 2001; 13; 180-185.
2. Coindre JM. Immunohistochemistry in the diagnosis of soft tissue tumours. Histopathology 2003; 43; 1-16.
3. Fanburg-Smith JC, Michal M, Partanen TA, Alitalo K, Miettinen M. Papillary intralymphatic angioendothelioma (PILA). A report of twelve cases of distinctive vascular tumor with phenotypic features of lymphatic vessels. Am. J. Surg. Pathol 1999; 23; 1004-1010.
4. Weninger W, Partanen TA, Breiteneder-Geleff S et al. Expression of vascular endothelial growth factor receptor-3 and podoplanin suggests a lymphatic endothelial origin of Kaposi's sarcoma tumor cells. Lab. Invest. 1999; 79; 243-251.
5. Partanen TA, Alialo K, Miettinen M. Lack of lymphatic vascular specificity of vascular endothelial growth factor recptor-3 in 185 vascular tumors. Cancer 1999; 86; 2406-2411.
6. Miettinen M, Lindenmayer AE, Chaubal A. Endothelial cell markers CD31, CD34, and BNH9 antibody. Mod. Pathol. 1994; 7; 82-90.
7. van de Rijin M, Rouse RV. CD34. A review. Appl Immunohistochem. 1994; 2; 71-80.
8. Folpe AL, Chand EM, Goldblum JR, Weiss SW. Expression of Fli-1, a nuclear transcription factor, distinguishes vascular neoplasms from potential mimics. Am. J. Surg. Pathol. 2001; 25; 1061-1066.
9. Breiteneder-Gefeff S, Soleiman A, Kowalski H et al. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries. Podoplanin as a specific marker for lymphatic endothelium. Am. J. Pathol. 1999; 154; 385-394.
10. Kahn HJ, Bailey D, Marks A. Monoclonal antibody D2-40, a new marker of lymphatic endothelium, reacts with Kaposi's sarcoma and a subset of angiosarcomas. Mod. Pathol. 2002; 15; 434-440.
11. Hahn HJ, Marks A. A new monoclonal antibody, D2-40, for detection of lymphatic invasion in primary tumors. Lab. Invest. 2002; 9; 1255-1257.
12. Erovic BM, Neuchirst C, Kandutsch S, Woegerbauer M, Pammer J. CD9 expression on lymphatic vessels in head and neck mucosa. Mod. Pathol. 2003; 16; 1028-1034.
13. Dabska M. Malignant endovascular papillary angioendothelioma of the skin in childhood: clinicopathologic study of 6 cases. Cancer 1969; 24; 503-510.
14. Guillou L, Fletcher CDM. Benign lymphangioendothelioma (acquired progressive lymphangioma): a lesion not be confused with well-differentiated angiosarcoma and patch stage Kaposi's sarcoma. Clinicopathologic analysis of a series. Am. J. Surg. Pathol. 2000; 24; 1047-1057.